ArticleGigaScience2025
Population-level allelic dispersion modeling by maelstRom yields genome-wide maps of allele-specific dysregulation during early carcinogenesis.
Article in GigaScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSince its inception, RNA sequencing has been pivotal in studying differential gene expression. Despite its extensive results in large-scale oncological studies, differential expression predominantly reflects a response to cancer. Therefore, we introduce differential allelic dispersion (AD) as a more effective measure. AD highlights consistent differences in expression between the 2 alleles of a gene that is, unlike cis-expression quantitative trait loci, independent of normal genetic variation. Such differences can, for example, arise from prevalent copy number alterations or epimutations occurring in the original cancer cell, which are mitotically expanded during cancer growth, making increased AD a marker for allele-specific dysregulation in early carcinogenesis.
findingsWe present the maelstRom R/C++ software package that enables (differential) AD analysis solely requiring large-scale RNA sequencing data. Using the The Cancer Genome Atlas renal clear cell carcinoma cohort as a case study, we successfully benchmark maelstRom's AD modeling using known copy number alterations. We also detect increased AD for loci featuring normal random monoallelic expression, including the X chromosome, but demonstrate minimal interference with cancer-specific AD detection. Finally, we identify early dysregulated genes (e.g., FBP1, CCDC8, ECHS1, CLDN7) and pathways in renal cancer, often related to metabolism (e.g., pentose phosphate pathway). Strikingly, many of these genes are known causal contributors to renal carcinogenesis.
conclusionsDifferential AD clearly indicates early dysregulation in renal cancer, complementing basic differential expression analysis in cancer transcriptomics. AD is also relevant to study random monoallelic expression and may equally detect allele-specific (dys)regulation during early development or in noncancer diseases. maelstRom is available as an open-source software package at github.com/Biobix/maelstRom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.